title: Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18).
abstract: The work presented here demonstrates that human complement factor H is an adhesion ligand for human neutrophils but not for eosinophils. The adherence of polymorphonuclear leukocytes (PMNs) to plastic wells coated with factor H depended on divalent metal ions and was augmented by C5a and TNF-alpha. PMN adhesion to factor H in the presence or absence of C5a was blocked specifically by mAbs against CD11b or CD18. Affinity purification using factor H Sepharose followed by immunoprecipitation using mAbs to various integrin chains identified Mac-1 (CD11b/CD18) as a factor H binding receptor. The presence of surface bound factor H enhanced neutrophil activation resulting in a two- to fivefold increase in the generation of hydrogen peroxide by PMNs stimulated by C5a or TNF-alpha. When factor H was mixed with PMNs, 1.4 to 3.8-fold more cells adhered to immobilized heparin or chondroitin A. In addition, augmented adhesion of PMNs was measured when factor H, but not HSA or C9, was absorbed to wells that were first coated with heparin or chondroitin A. The adhesion of PMNs to glycosaminoglycan-factor H was blocked by mAbs to CD11b and CD18. These studies demonstrate that factor H is an adhesion molecule for human neutrophils and suggest that the interaction of factor H with glycosaminoglycans may facilitate the tethering of this protein in tissues allowing factor H to serve as a neutrophil adhesion ligand in vivo.
authors.affiliation: The La Jolla Institute for Experimental Medicine, CA 92037, USA.
authors.forename: R G
authors.initials: RG
authors.lastname: DiScipio
authors.forename: P J
authors.initials: PJ
authors.lastname: Daffern
authors.forename: I U
authors.initials: IU
authors.lastname: Schraufstätter
authors.forename: P
authors.initials: P
authors.lastname: Sriramarao
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001798:Blood Proteins / Q000378:metabolism; D018821:CD18 Antigens / Q000378:metabolism*; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology; D015936:Complement C5a / Q000494:pharmacology; D017242:Complement Factor H / Q000378:metabolism* / Q000494:pharmacology; D006025:Glycosaminoglycans / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D016209:Interleukin-8 / Q000494:pharmacology; D007781:Lactoferrin / Q000378:metabolism; D008024:Ligands; D016177:Macrophage-1 Antigen / Q000302:isolation & purification / Q000378:metabolism*; D009504:Neutrophils / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D016877:Oxidants / Q000378:metabolism; D011485:Protein Binding; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D001798:Blood Proteins; D018821:CD18 Antigens; C493495:CFH protein, human; D006025:Glycosaminoglycans; D016209:Interleukin-8; D008024:Ligands; D016177:Macrophage-1 Antigen; D016877:Oxidants; D014409:Tumor Necrosis Factor-alpha; D015936:Complement C5a; D017242:Complement Factor H; D007781:Lactoferrin